37 results about "Colonic adenocarcinoma" patented technology

The invention relates to a molybdenum compound [MoO2Cl2(H2O)2][15C5] of 15-crown-5 and molybdenum, preparation method and application thereof. The molybdenum compound provided by the invention can prevent and inhibit the formation and growth of cancers and tumors, and can be used for preparation of drugs preventing and treating cancer and tumor diseases. Synthesis of the compound drug provided by the invention has the characteristics of easily available raw materials and low cost, the product precipitates out in the form of crystals, has high purity and yield, can stably exist under natural state, has good water solubility and lipid solubility, and presents excellent inhibition effect on A-549 (lung cancer), Bel-7402 (liver cancer), and HCT (colonic adenocarcinoma).

The invention relates to a nano-material cell-based biosensor, a preparation method thereof and a new method using the nano-material cell-based biosensor to evaluate the antioxidant activity of antioxidant polypeptides and relates to the field of antioxidant capacity measuring. Colonic adenocarcinoma cells are used as the sensing elements to build a cell gel three-dimensional network structure, and the cell gel three-dimensional network structure is combined with nano-material modification electrodes to evaluate the antioxidant activity of the polypeptides. The method using the cells to simulate electrochemical signals so as to evaluate the antioxidant activity of the polypeptides is novel and convenient in detection and has high practicality in the comprehensive evaluation of the cell protection effect of antioxidant substances.

The invention relates to a new application of furanodiene in pharmacy field, in particular to the application of the furanodiene in the preparation of medicines for treating the various malignant tumor diseases such as oophoroma, cervical carcinoma, gastric cancer, liver cancer, leucocythemia, lung cancer, oral carcinoma (epidermoid carcinoma), rectal adenocarcinoma, mammary cancer, malignant melanoma, colonic adenocarcinoma, nasopharyngeal carcinoma, carcinoma of prostate, etc. The invention also relates to the application of the furanodiene in the preparation of drugs for treating the diseases caused by herpesvirus, influenza virus and hepatitis B virus.

The invention relates to the field of medicinal chemistry, and in particular, relates to an application of a brefeldin A derivative represented by a formula (I) in the aspect of inhibiting tumor proliferation activity. The novel compound has outstanding effects in preventing or treating hyperproliferative diseases including liver cancer, leukemia, breast cancer, colonic adenocarcinoma, gastric cancer, lung cancer, Bartter's esophagus cancer, cervical cancer, pancreatic cancer, endometrial cancer, bone cancer, lymph cancer, kidney cancer, brain cancer, nerve cancer, nasopharynx cancer, oral cancer and colorectal cancer, and has the potential of being developed into a novel antitumor drug.

The invention discloses a primer capable of detecting the methylation of a promoter of a gene related to colonic adenocarcinoma. The primer which is used for detecting the methylation of a DNA (Deoxyribonucleic Acid) to be detected provided by the invention consists of a primer pair A, a primer pair B, a primer pair C, a primer pair D, a primer pair E and a primer pair F, wherein the primer pair A consists of a primer 1 and a primer 2, the primer pair B consists of a primer 3 and a primer 4, the primer pair C consists of a primer 5 and a primer 6, the primer pair D consists of a primer 7 and a primer 8, the primer pair E consists of a primer 9 and a primer 10, the primer pair F consists of a primer 11 and a primer 12, and nucleotide sequences of the primers 1-12 are sequences 1-12 in the sequence table. When the primer capable of detecting the methylation of the DNA is adopted, a Tm value of the primer can be controlled at 60 DEG C, specificity and amplification efficiency of a PCR (Polymerase Chain Reaction) product are ensured, and methylated state of samples of colonic adenocarcinoma and adenoma can be efficiently detected.

The invention provides a method for establishing a tumor cachexia model of deficiency syndrome. The method comprises, at the same time, adopting the three-factor induction method of bitter cold diarrhea, hunger and fullness, and exhausted exercise to establish a deficiency syndrome mouse model, and inducing it for 7-15 days; inoculating the obtained deficiency syndrome mice with C26 colon adenocarcinoma cells to obtain deficiency syndrome Tumor cachexia model: After inoculation, the two-factor induction method of bitter cold diarrhea and abnormal hunger and fullness is adopted at the same time, and the induction is continued for 15‑18 days. Among them, body weight, thymus weight, spleen weight, and gastrin content were selected as observation indicators for deficiency syndrome. The animal model established by the above method can be used to study deficiency syndrome tumor cachexia or to screen drugs for treating deficiency syndrome tumor cachexia.

The invention relates to the field of medicinal chemistry, and in particular, relates to an application of a brefeldin A ester derivative in inhibiting tumor proliferation activity, wherein the structure of the brefeldin A ester derivative is represented by a formula (I). The novel compound has outstanding effects in preventing or treating hyperproliferative diseases including liver cancer, leukemia, breast cancer, colonic adenocarcinoma, gastric cancer, lung cancer, Bartter's esophagus cancer, cervical cancer, pancreatic cancer, endometrial cancer, bone cancer, lymph cancer, kidney cancer, brain cancer, nerve cancer, nasopharynx cancer, oral cancer and colorectal cancer, and has the potential of being developed into a novel antitumor drug.